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Abstract
Background: Genomic techniques are being developed within oncology and begin‐
ning to be experienced within routine cancer care. Little is known about how these 
tools feature in patients’ experiences of treatment decision making.
Objective: This research explores the ways in which women interpret and discuss 
gene expression profiling for breast cancer treatment decision making, as articulated 
within online accounts.
Design: This study used a qualitative approach to analyse written exchanges focusing 
on gene expression profiling in the UK (Oncotype DX test). Accounts are taken from 
online forums hosted by two UK cancer charity websites, comprising 132 discussion 
threads from a total of seven forums. Authors qualitatively analysed the data and 
developed key themes drawing on existing literature from medical sociology.
Findings: Women used online spaces to share and discuss results of gene expression 
profiling. Women interpreted results in the context of indirect experience of cancer 
treatment, and sociocultural depictions of cancer and chemotherapy. Users largely 
represented the test positively, emphasizing its ability to “personalize” treatment 
pathways, though many also pointed to inherent uncertainties with regards the pos‐
sibility of cancer recurrence.
Discussion and Conclusions: We highlight the complex contexts in which genomic 
techniques are experienced, with these shaped by personal biographies, online envi‐
ronments and pervasive cultural narratives of cancer and its treatment. We highlight 
tensions between the claims of genomic testing to aid treatment decision making and 
patient reflections on the capability of these techniques to resolve uncertainties sur‐
rounding treatment decisions.
K E Y W O R D S
breast cancer, chemotherapy, decision making, gene expression profiling, internet research, 
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1  | INTRODUC TION
A key feature of contemporary medicine is the incorporation of mo‐
lecular information within clinical pathways to understand and act 
upon disease.1 This is particularly visible within oncology, where it is 
anticipated that the identification of specific genetic alterations 
within tumours will lead to treatment regimes tailored to individual 
patients.2 As an example of this novel approach, gene expression 
profiling may now be offered as part of routine National Health 
Service (NHS) breast cancer care for a subgroup of patients. This 
technique is used to assist decision making around adjuvant chemo‐
therapy, a treatment administered following surgery to reduce the 
likelihood of cancer returning. For some early- stage breast cancers,* 
the predicted benefit of chemotherapy for preventing recurrence 
may be unclear when assessed on protein receptor status and tu‐
mour grade alone. Available as part of NHS care as of April 2015 
(initially in England), the Oncotype DX test uses gene expression pro‐
filing to predict the risk of cancer recurrence in these patients and 
identify those who are most likely to benefit from adjuvant 
chemotherapy.
Oncotype DX assesses the activity of 21 genes in breast can‐
cer tissue. The corresponding results are prognostic, indicating 
the likelihood of a woman’s cancer returning within 10 years 
when treated with hormone therapy alone. The cancer is as‐
signed a continuous “recurrence score” (from 0 to 100), and a risk 
category for recurrence: low (<18), intermediate (18- 30) or high 
(≥31).3 The recurrence score is a predictor of benefit from the 
addition of chemotherapy to hormone therapy for disease- free 
survival.4 In clinical practice, both the score and risk categoriza‐
tion are used by clinicians and patients to assist chemotherapy 
decisions. For those positioned at low risk of recurrence, studies 
have suggested that these patients are unlikely to derive great 
benefit from adjuvant treatment.5 Patients in this category are 
not recommended to proceed with chemotherapy,6 which is it‐
self associated with (sometimes severe) side- effects and suffer‐
ing.7 Chemotherapy is recommended for those patients with a 
high recurrence score, as it has been shown to bestow signifi‐
cant advantage for disease- free survival compared with hormone 
therapy alone.4 For those placed in the intermediate category, 
recommendations for chemotherapy are less clear (though a re‐
cent clinical trial has indicated that women with an intermediate 
score may be spared chemotherapy8). In the case of an interme‐
diate score, treatment recommendations often involve further 
discussions with the patient, alongside consideration of wider 
clinical parameters and patient preferences.6,9
In 2013, guidance published by the National Institute for Health 
and Care Excellence (NICE) acknowledged the uncertainties sur‐
rounding treatment decision making for patients with early- stage 
breast cancer of this type and recommended that Oncotype DX be 
adopted by the NHS:
Breast cancer patients face significant emotional and 
psychological strain when considering chemotherapy. 
It can be particularly distressing for patients in whom 
the decision to have chemotherapy is unclear… Tools 
or tests that help people decide whether or not to 
have chemotherapy are likely to be greatly appreci‐
ated by patients.3
Here, the availability of gene expression profiling is positioned as 
a positive development for individual patients, by “helping people to 
decide” whether to proceed to chemotherapy. Discerning who may 
(not) benefit most from chemotherapy is also important from a policy 
perspective, with the “over- treatment” of breast cancer having impli‐
cations for health service costs and delivery.3,10 Though social scien‐
tific research has explored clinicians’ experiences of interpreting gene 
expression tests9 and their impact on professional roles and identity,11 
less attention has been given to the ways in which these tools fea‐
ture in patient decision making with regards treatment, or the role they 
play in experiences of cancer more widely. This is important for pol‐
icy and practice; it has been established that chemotherapy decisions 
are shaped by social contexts, familial relationships and wider health 
histories, but little is known about how novel prognostic techniques 
intersect with these. In this article, we explore some of these factors as 
articulated by women within online accounts.
Existing sociological research has shown that medical decision 
making by patients is complex and situated. Treatment decisions 
may be thought of as “distributed”12—shared amongst patients, 
their families, clinicians and wider social networks, and as occurring 
across time and space.13 Although patient participation in decision 
making is advocated within medical practice, it has been reported 
that patients vary in the degree to which they wish to take full 
ownership over treatment decisions in health care.14,15 Alongside 
contemporary shifts in the provision of care, individuals are also 
seeking advice and support for medical decision making beyond the 
clinic through virtual platforms.16 The Internet can be a source of 
second opinions, advice regarding symptoms or side- effects, and 
information about tests and treatments for those experiencing 
cancer.17 Indeed, access to others’ experiences of a shared health 
condition has been highlighted as a key aspect of online informa‐
tion seeking, with first person accounts of illness shaping treatment 
choices and the very experiences of ill health.18 As categorizations 
of (some) cancers and treatment pathways become more diffuse, 
patients are today presented with large amounts of information 
about their condition and a range of different options, including 
novel therapies and clinical trial participation. In this context, in‐
sight into other patients’ experiences and choices may be more sa‐
lient, as individuals become more active in choosing treatments and 
options for long- term management.
To improve understanding of how novel techniques might be 
shaping patient decision making, in what follows we explore wom‐
en’s experiences of gene expression profiling (Oncotype DX) in 
early- stage breast cancer, as discussed within postings on UK online 
forums.
*Generally breast cancers that are human epidermal growth factor receptor 2 (HER2) neg‐
ative, oestrogen receptor (ER) positive and lymph node- negative. 
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2  | METHODS
2.1 | Rationale
The online research presented here took place alongside qualitative 
interviews for a wider study exploring experiences of genomic tech‐
niques within contemporary oncology research and practice. The 
design of the research has been informed by members of two patient 
and public involvement (PPI) panels, who have raised predictive and 
diagnostic genomic testing as a topic of concern. Conversations with 
panel members suggested that these tests may produce false nega‐
tive/positive or inconclusive results and indicated that uncertainties 
inherent within genomic testing should be discussed with patients 
and their families. As a recent introduction to NHS management of 
breast cancer, and with scant qualitative exploration of patient expe‐
riences, Oncotype DX testing was identified as a relevant technique 
through which to explore such issues within the remit of the wider 
research project.
The selection of online forums to access experiences of this 
healthcare technology was also informed by meetings with PPI panel 
members. Members have discussed the issue of diversity in experi‐
ences of cancer care, and the difficulties that may be faced by those 
who are “socially excluded” in articulating questions or complaints 
about care with health professionals. Online forum data provide ac‐
cess to such reflections, with Internet communication often used by 
individuals to follow- up clinical diagnoses and compare clinical infor‐
mation with other users.18 Further, online forums provide access to a 
range of experiences from a large number of geographically diverse 
individuals, who may be excluded from face- to- face forms of quali‐
tative research due to disability or their omission from opportunities 
to participate.19 The method also responds to a recognition within 
the social sciences that Internet use is enmeshed with contempo‐
rary experiences of health and illness.16,20 Indeed, as landscapes of 
disease categorization and treatment shift in line with advances in 
prognostic testing and therapies, decision making in cancer care is 
becoming more complex.21 This has implications for online spaces 
and their functions, with these subject to ongoing reconfiguration.
2.2 | Data
To gather online accounts of women’s experiences, two authors 
(ER and JS) searched for the term “Oncotype” within publically ac‐
cessible online forums, hosted by two UK cancer charity websites: 
one supporting all cancer types and the other a breast cancer char‐
ity. Posts included in analysis were limited to those authored from 
April 2015, when the test was approved for NHS use, until May 
2017. Discussion threads identified by the search were copied into 
Microsoft Word documents to facilitate qualitative analysis. This 
application was favoured over Computer Assisted Qualitative Data 
Analysis Software (CAQDAS) to enable easier movement between 
analytic memos, which were recorded alongside the text itself using 
the “comments” function.
Searches yielded a large amount of data. By way of example, 
one of the seven online forums featuring the word “Oncotype” 
contained 68 threads within the date range. Discussion threads 
on this forum contained between 4 and 75 individual posts. To 
generate a manageable dataset, data from two forums on the 
breast cancer charity website were excluded from analysis. These 
two forums focused on (a) experiences of recent diagnosis and (b) 
discussion of more general topics beyond cancer. Threads where 
Oncotype DX did not form the substantive content of discussion 
were excluded from the recent diagnosis forum, for example 
if the technique was merely named when recounting treatment 
pathways. The largest threads excluded here were from women 
seeking emotional support for specific aspects of their cancer ex‐
periences, for example questioning whether their emotions were 
“normal” (137 pages), and when feeling “low” (118 pages). A total 
of 32 threads, comprising 950 pages, were excluded, as well as an 
additional ongoing thread containing over 5000 posts; this also 
centred around support in the context of recent diagnosis. In the 
general discussion board, a total of two threads were excluded 
comprising 433 pages. The first was a thread welcoming users to 
the forum, and the second concerned a user seeking advice with 
regards her mother’s cancer treatment.
Included threads encompassed comments from those who had 
not undergone the test themselves, but who had outlined anec‐
dotal or media reported information about the Oncotype DX test, 
and from those who had unsuccessfully attempted to access gene 
expression profiling. From the cancer- wide website, 53 discussion 
threads from one forum were taken forward to analysis, and from 
the breast cancer charity website, 79 threads from six forums were 
included. This gave a final dataset of 132 discussion threads, com‐
prising 639 pages.
2.3 | Data analysis
Analysis took a thematic approach, aligned with the analytic process 
described by Braun and Clarke.22 The content of entire discussion 
threads selected for analysis was read by each author conducting the 
search, who “constantly compared”23 the text within and between 
threads. This was performed with reference to existing sociological 
literature on cancer illness narratives, biomedicalization and treat‐
ment decision making. This process was also informed by ongoing 
PPI activities, during which differences in individual patients’ desires 
to engage with clinical information have been emphasized, as have 
the uncertainties faced by patients when given information about 
diagnosis and prognosis. With this literature and PPI insight in mind, 
ER and JS each developed key themes from their set of data, which 
were shared electronically and deliberated during several in- person 
meetings. Each author then examined both sets of themes and as‐
sociated extracts, and grouped relevant quotes and concepts within 
refined key themes. These were then shared between all authors 
and discussed and developed drawing on verbatim data, to cultivate 
overarching focal points for the presentation of findings.
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2.4 | Ethical considerations
Online methods of data collection for sociological research are sub‐
ject to wider ethical guidelines associated with the discipline, with 
safeguarding the interests of those involved in or affected by the 
research remaining paramount.24 However, the use of online mate‐
rial demands new ethical considerations, with issues of informed 
consent, anonymity and confidentiality not adequately addressed by 
guidelines applied to more established research methods. In line with 
the deliberative process advocated by the Association of Internet 
Researchers,25 we consulted existing online research studies when 
deciding upon our strategy. Due to the personal nature of the ac‐
counts presented within online forums, we contacted forum mod‐
erators in May 2017 seeking permission to use individual posts in 
our research, which was granted. Our approach to the use of online 
data was approved by departmental Research Ethics Committees at 
the University of Edinburgh and University of Leeds. To ensure ano‐
nymity, as far as is possible with online research, we have assigned 
updated pseudonyms to users and excluded identifying information 
in the findings reported below. Dates of individual posts are included 
to demonstrate the ongoing nature of contributions by individual au‐
thors and continued resonance of key themes over time.
3  | FINDINGS
In what follows, we show how the Oncotype DX test was rep‐
resented by women using online forum spaces. We then go on to 
discuss how women described test results and their role in chemo‐
therapy decision making, with this shaped by indirect experiences of 
cancer treatment, and sociocultural depictions of cancer and chemo‐
therapy. Finally, we outline how users discussed the test in relation 
to inherent uncertainties with regards the success of treatment and 
possibility of cancer recurrence. In doing so, we highlight tensions 
between the claims of genomic testing to aid treatment decision 
making, and the uncertainties and anxieties which the procedure 
could provoke or leave unresolved.
3.1 | Representations of gene expression testing 
within online environments
Many discussions of Oncotype DX represented the test as facili‐
tating treatment decision making, echoing the rationale outlined 
within the 2013 NICE guidance cited above. For example, one user 
of a cancer support charity forum explained that gene expression 
profiling “help[s] make informed decisions about chemo[therapy]” 
(DiamondMary, Jan 2017), and another declared she was “glad I took 
the test because it did help my decision in the end” (SandyP, Jan 
2017).
Related to this, several users emphasized the test’s ability to 
provide “personalized” information about cancer. For example, one 
woman advised others to undergo the test because “it’s based on 
you and you can then make an informed decision” (Stacey1954, Jan 
2016). Another described that “what it does is show whether your 
specific tumour cells would benefit from chemo” (Telophene, Jun 
2017). Due to the ability to provide what many discussed as a “spe‐
cific” prediction of cancer recurrence, some represented Oncotype 
DX as providing certainty:
The onco[type DX] test is a very good test, which 
provides statistical evidence based upon your tu‐
mour. It’s tailor made and was designed so that it 
takes the guess work out of whether you will benefit. 
 DiamondMary, May 2016
In expressing its ability to provide “tailor made” information, some 
juxtaposed gene expression profiling with other sources of information 
used by clinicians to predict the benefit of adjuvant chemotherapy. This 
included the NHS PREDICT tool, an algorithm used by oncologists to 
guide chemotherapy decision making. In addition to being used by cli‐
nicians, this can be freely accessed by patients online. One user noted 
that although the Oncotype DX is “not infallible,” it is preferable to:
the original %s which were based on averages of pa‐
tients with similar diagnosis […] [Oncotype DX] actu‐
ally tests your tumour so it is only based on your data 
[…] it is a lot more personal and specific.  Lizdene, Jun 
2016
Scepticism of these more widely used tools was also visible 
amongst others, with MayP (January 2017) describing these as “only 
a general indicator based on past recovery data that can be quite old.” 
In the same thread, Pumpkin noted that where “generalised tools could 
be very wrong,” Oncotype DX is “an individual test for you,” which 
she interpreted as providing more surety with regards her treatment 
decision.
Betty45, who had not experienced gene expression profiling her‐
self but was living with a heart condition she attributed to chemo‐
therapy, displayed a particularly positive view of the technology. She 
invoked a hopeful future by saying “I think the answer for a large 
percentage of us will be the Oncotype DX test which shows whether 
chemo will work or not” (Nov 2015). Some thus positioned the test 
as not only providing certainty, but also as having the potential to 
transform breast cancer care.26,27 Although this was not reflective 
of all users, with many also depicting the test not as a tool that elim‐
inated guesswork, but one that “refined” guesswork, positive reflec‐
tions on the test’s role in decision making were visible throughout 
forum posts. In many cases, these could efface the complex and rela‐
tional contexts within which decision making arose, which were also 
articulated within forum discussions. This is discussed further below.
3.2 | Gene expression testing and treatment 
decision making
Oncotype DX’s production of a single figure to indicate recurrence 
risk, and corresponding recommendation to proceed (or not) to 
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chemotherapy, was welcomed by many women. Some attributed a 
particular power to the test score in shaping their treatment choices. 
This was evident in reflections on the implications of forthcoming 
results. For example, two users declared:
[…]if it came back as high risk I would have to [undergo 
chemotherapy]  KyliePear, May 2016
I know if my score is high then I cannot refuse [chemo‐
therapy].  HazelKew, April 2017
Some users stressed Oncotype DX results when advising those 
who were unsure about whether to proceed to chemotherapy. As one 
woman noted, “[the score] suggested chemo would be of benefit to 
you. Can you really afford to go against that?” (DiamondMary, March 
2017). The power and influence attributed by some to the test result in 
treatment decision making were perhaps most evident in representa‐
tions of test results in the context of not proceeding to chemotherapy. 
For those who had received a low risk score and not proceeded to ad‐
juvant chemotherapy, test results were often depicted as determining 
this decision, seen in the extracts below:
Had oncotype [DX] score of 15 which means no che‐
motherapy  HeidiD, Jan 2017
I have [an] Oncotype DX score of 17 so no chemo 
 MollyC, Feb 2017
These crude presentations of treatment pathways were com‐
mon on the forum posts we analysed. Here, we see that uncertain‐
ties surrounding the prediction of recurrence risk, and complexities 
of treatment decision making visible within other forum responses, 
and described within existing sociological literature [eg, 12,13], were 
obscured. These users depicted their decision not to go ahead with 
chemotherapy as fully predicated on their gene expression profiling 
test result. By describing chemotherapy choices in this way, online ac‐
counts of gene expression results suppressed the uncertainties inher‐
ent within (recurrence) risk prediction, instead presenting test scores 
as a “hard reality” inspiring (in)action and emotional responses.28 For 
one woman, a score placing her at “high risk” of recurrence led her to 
defy a personal preference to avoid chemotherapy, for which she had 
previously “fought”:
I had the Oncotype test and got a score of 47 so it was 
a very easy decision for me. (Until I got the result I was 
fighting tooth and nail to avoid chemo, but I listened 
to the data.)  CancerBeater, Jul 2016
As seen above, presentations of the test score as authoritative 
were particularly evident amongst women attaining a low score, 
who often portrayed their chemotherapy choice as unambiguous 
(though of course, this was not necessarily experienced as such). 
In contrast, women attaining intermediate (and to a lesser extent 
high) scores generally described treatment decision making follow‐
ing Oncotype DX as more complex, fraught and fragmented within 
their forum posts. Unlike high and low designations of recurrence 
risk, the intermediate risk category is not associated with clear 
guidance with regards adjuvant chemotherapy. Throughout posts, 
this was described as the “up to you zone” (SueDev April 2017) or 
the “grey zone” (Ursula32, Jan 2017). Maeve (April 2017) described 
that an Oncotype DX test result of 26 had caused her “more worry 
than my operations, anxiety and desperation.” Women in 25 dis‐
cussion threads had received an intermediate result, and of these 
threads, 13 included contributions from women explicitly asking 
for input into decision making.
In many of these cases, the score became a powerful and direct 
representation of their current and possible future experiences of 
cancer, able to be shared with others within this online environment. 
Indeed many forum users cited their own results when seeking ad‐
vice to negotiate the meaning of an intermediate score:
Today the test has not really helped. Basically I’m slap 
bang in the middle! Score was 21[…] The chemo could 
help but it’s a low percentage. [The oncologist] said 
I have the overall decision. So hard! I don’t want to 
ever have to regret thinking I should have had it, but 
statistically it’s very small amount of possible help[…] 
Confused! Any advice most appreciated.  SueDev, 
April 2017
This extract represents a common tension observed in women’s 
posts, with women situated between a resistance to undergoing che‐
motherapy (particularly where they understood this could be of little 
benefit), and a felt imperative to avoid cancer recurrence by consent‐
ing to further treatment. SueDev invokes a notion of future “regret” 
as shaping her treatment decisions. This accords with language used 
by patients within existing studies, whereby cancer is positioned as 
an enemy that patients are responsible for “fighting”,29 with “good” 
patients identified as those who identify and actively manage risks of 
recurrence.30,31 However, for many, this fight entails chemotherapy, a 
treatment associated culturally and experientially with long- term side- 
effects and suffering.7 To overcome some of the difficulties of making 
choices within these evocative contexts, users placed in the interme‐
diate range described manipulating these numerical signifiers to aid 
decision making. This included re- adjusting thresholds, reconstituting 
risk categories or positioning themselves differently within these to aid 
decision making:
My score was 23, which is a medium risk but on the 
lower side of medium. And I would only benefit from 
chemo another 4% so I don’t need it.  Iris, July 2015
The other factor influencing my decision was the 
knowledge that studies have been conducted where 
the intermediate group was redefined as 11 to 26 
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which put me firmly into the High category.  Bonne, 
December 2016
Some women with experience of the test advised others to devise 
personal thresholds prior to receiving results:
It’s important you have a cut off point going in….
mine was 18- 24 and they would really have to sell me 
chemo.  SunshinePeggs, April 2017
Though depicted as powerful determinants of chemotherapy de‐
cision making within some online posts, these examples show that 
Oncotype DX results and associated recommendations for chemo‐
therapy were not interpreted so unambiguously by all users. Instead, 
(anticipated) Oncotype DX results could be engaged with by patients 
in varying ways. Interpretations of test scores thus cannot be reduced 
to their “objective” biomedical significance, but must be understood as 
shaped by and shaping shared experiences of patient collectives, and 
the wider meanings of cancer and its treatment.32
3.3 | Attending to uncertainty?
Despite some women attributing the gene expression profiling re‐
sult with particular authority in shaping treatment choices, others 
expressed scepticism of the test’s ability to aid treatment decision 
making. Some users noted that despite clinician opinion, statistics 
and test results, ultimately there “are no crystal balls” (GrannyG, April 
2017). In some cases, this was linked to the elusive and insidious na‐
ture of cancer as a disease, with posts describing “rogue” or “stray” 
tumour cells. Users’ experiences, including memories of historical 
treatment, reinforced this sense of the unpredictability of cancer. 
For example:
Just 2 years after finishing Chemo I was diagnosed 
with bone [metastases] to my sternum! So a sneaky 
cell managed to hide from the chemo…..I suppose 
what I’m saying is Chemo doesn’t necessarily give you 
100% guarantee!  SouthernGirl, Feb 2017
I met two ladies who were back for a recurrence de‐
spite having had chemo and radiotherapy, so it seems 
as if it’s just a roll of the dice anyway.  Huggy, August 
2015
Some women described that ultimately, biomedical knowledge and 
techniques could not provide a definitive answer as to whether their 
cancer would recur, and as to whether chemotherapy was an appro‐
priate option. As such, some users discussing Oncotype DX results ar‐
ticulated that the onus was on themselves to make the final decision 
with regards chemotherapy. This ultimate uncertainty can be linked to 
posts emphasizing the ability of cancer to evade detection, with med‐
ical techniques unable to confirm whether their cancer had been re‐
moved in its entirety. SouthernGirl elaborated further:
None of us can see into the future, so we have to 
make a decision on the information we have.
As we have seen above, the “information we have” went beyond 
test results and clinical judgement, to indirect experience and expecta‐
tions of treatment. Embodied and relational elements of decision mak‐
ing following gene expression profiling were also emphasized by forum 
users. Responding to posts seeking advice with regards chemotherapy 
choices, users were often encouraged to make decisions that were per‐
sonal to their circumstances, or based on emotion or embodied expe‐
rience, by doing what “feels right” FionaO, Jan 2017. Reflecting on her 
negotiation of intermediate category, one user drew on the biological 
characteristics of her specific tumour type to inform her decision, but 
ultimately gave authority to personal “feeling”:
I am waiting for my oncotype dx result and have de‐
cided that if it is a middling result and I get a say then I 
will have the chemo as my cancer is grade 3 and an ag‐
gressive little thing and because I am a natural worrier 
so know if I don’t have it it will pray on my mind after‐
wards but everyone is different - in this situation how 
you feel is more important than statistics.  GrannyG, 
April 2017
Potential future emotions were also emphasized, should one refuse 
chemotherapy only for their cancer to return:
I was in a similar boat last December […] I wanted to 
take whatever risk reduction I could get so I went with 
it. I also kept thinking ‘what if I don’t’… how would I 
feel if there was recurrence and I hadn’t chosen to go 
through with chemo?  Explorer, March 2016
As we have seen, the emphasis on the personal was informed by 
cultural narratives and memories of cancer and treatment, and an em‐
bodied sense of vulnerability to cancer cells.33 In these contexts, wom‐
en’s responses to gene expression profiling test results are therefore 
not easily predicted; for example, those with a low recurrence score 
did not always indicate that they would eschew chemotherapy. In what 
follows, we discuss our findings, and their implications for sociological 
explorations of treatment decision making in the context of novel bio‐
medical techniques.
4  | DISCUSSION
Our analysis of online forum discussions has begun to capture how 
individuals are negotiating gene expression profiling, as they docu‐
ment reflections on this technology in online spaces. Comments 
from some women positioned Oncotype DX results as “personal‐
ized,” interpreting the information it provides as “tailored” to their 
cancer, and as superior to existing techniques assisting chemo‐
therapy decision making. This may be shaped by wider discourses 
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of hope and hype surrounding the potential of genomic medicine, 
highlighted in existing sociological studies [see 2,26]. The quantifica‐
tion of potential recurrence risk as a single score was a particularly 
powerful characteristic of the test for some women. Oncotype DX 
results allowed for the sharing of what was interpreted as personal 
risk, with women disclosing scores in online forums to seek individu‐
alized support from others. This accords with existing social scien‐
tific research, which has shown that numerical presentations of risk 
attained through molecular techniques can provide reassurance for 
individuals post- treatment [see 32], by increasing certainty and con‐
trol in the context of disease.
Nevertheless, despite its purported aim to facilitate treatment 
decision making by predicting recurrence and estimating chemo‐
therapy benefit for individual women, Oncotype DX testing could 
be experienced as ambiguous. Other work has shown that the quan‐
tification of risk to guide treatment may invoke vulnerability for pa‐
tients, provoking a sense of foreboding and insecurity by situating 
individuals in a space between health and illness.28 This research has 
shown some of the ways in which the gene expression profiling re‐
sult, presented as a singular, numerical representation of recurrence 
risk, was open to interrogation by women. Users interpreted results 
in light of more widely adopted techniques used to estimate recur‐
rence risk, such as protein receptor status, and algorithms founded 
on population data. Understandings articulated by individual women 
were situated within emotional responses to chemotherapy and 
cancer in the present, but also possible futures and long- term con‐
sequences of decision making. Through the accounts described 
above, we have also demonstrated that interpretations of results 
are informed by sociocultural depictions of cancer and treatment, 
with chemotherapy and suffering depicted as necessary to recover 
from cancer [see 7,31,34]. Several women discussed the potential 
for regret at not proceeding to chemotherapy, in some cases linked 
to perceptions of the disease as insidious, and women’s awareness of 
the inability of biomedical tools to detect “stray” cells.
Decision making was particularly complex where recurrence 
scores signalled an intermediate risk of cancer recurrence. In these 
cases, women often appealed to other forum users for guidance on 
treatment decisions, and most clearly articulated a sense of being 
positioned between an imperative to treat cancer and cultural nar‐
ratives of chemotherapy as entailing suffering.7 Further, these de‐
cisions took place within a context of wider observations of cancer 
and its recurrence, where the disease was shown to ultimately be 
unpredictable, and treatment efficacy uncertain. Many women were 
thus aware of the limitations of gene expression profiling, which re‐
mained unable to provide a definitive answer as to whether their 
cancer would recur, or whether chemotherapy would be able to pre‐
vent recurrence. In some cases, women thus encouraged others to 
privilege experiential or affective knowledge in chemotherapy deci‐
sion making, over the test score itself [see also 35].
Overall, our analysis has shown that gene expression profiling 
did not always straightforwardly facilitate decision making with 
regards proceeding to chemotherapy. This is despite the fact that 
some forum users represented the test as determining choices. For 
many women, the test score was not interpreted as clear- cut, instead 
results were given meaning and transfigured in light of personal ex‐
periences, sociocultural discourses of cancer and chemotherapy, and 
the limitations of, or expectations for, novel techniques in cancer 
care. This has implications for the use of genomic prognostic testing 
within the health service, with clinician- patient discussions of test 
scores needing to account for varying interpretations of the meaning 
of these results, as well as differing and very personal experiences of 
anxiety surrounding cancer.33,34
Online forums were depicted by users as playing a role in wom‐
en’s negotiations of these novel techniques. Accessing and inter‐
acting within online spaces further distributes decision making, as 
treatment options themselves become more diffuse. Patients are 
today required to make sense of new forms of clinical information 
and medical techniques, with these experienced by smaller, sub‐
groups of individuals. Women used online forums to document 
competing treatment options and emotions, to share experiences 
and to seek advice from others. Online research methods therefore 
enabled us to observe aspects of decision making as an evolving pro‐
cess distributed amongst a wide range of settings and individuals, 
enrolling unknown and anonymous others over time and space.12,13
Whilst online forums have provided insight into intimate ac‐
counts of treatment decision making as shaped by gene expression 
profiling, their use to access women’s experiences does have limita‐
tions. We cannot say with certainty that we were able to capture 
accounts from a diverse group of women, with Internet access likely 
to reflect wider social and structural inequalities.36 This research, 
however, did not intend to be generalizable in a statistical sense, but 
to shed light on the breadth and potential complexity of decision 
making in the context of a novel genomic technique.37 The absence 
of in- depth narratives, with analysis focusing on short posts which 
were sometimes devoid of context, has also meant that we were not 
able to explore wider impacts on decision making in great depth. 
Further research is required to learn more about how patients seek 
and share information with others, and the impact of online forum 
use itself on decision making about cancer treatment. This may offer 
guidance to patients and clinicians about how online forums might 
be best used at this difficult time. These issues are being addressed 
by complementing this online research with ongoing qualitative 
interviews.
5  | CONCLUSION
This study of accounts of gene expression profiling has shed light on 
how women are engaging with and negotiating novel genomic tech‐
niques as they become integrated within routine cancer care in the 
UK, and the resources they draw on in this regard. Importantly for 
clinical practice, we have shown that the women represented in this 
research did not always interpret Oncotype DX scores straightfor‐
wardly, with these results taking on varying significance according 
to factors including personal encounters with cancer, and potential 
regret for declining treatment. This emphasizes the importance of 
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holistic treatment decision making between patients and clinicians, 
which may engage with loved ones’ experiences of the disease, “gut 
feelings,” emotions and anticipated futures.
Online forums have proved to be a valuable resource to explore 
perceptions of gene expression profiling as articulated by women in 
the midst of chemotherapy choices. These are also emblematic of 
the contemporary distribution of decision making, which has the po‐
tential to become reconfigured as genomic techniques and “person‐
alized” treatment regimes become further integrated within clinical 
care. In- depth qualitative research will provide deeper insight into 
the emotional and embodied elements of these treatment choices, 
and their interplay with genomic techniques alongside more estab‐
lished means of informing treatment decisions in cancer care.
ACKNOWLEDG EMENTS
We are grateful to the anonymous online forum users whose com‐
ments are featured in this research and to forum moderators for con‐
senting to our use of this material for our study. Thank you to Breast 
Cancer Care and Macmillan Cancer Support. We also acknowledge 
participants in our PPI panels for their contributions to our research 
and to the anonymous reviewers for their insightful feedback.
CONFLIC T OF INTERE S T
The authors have no conflict of interest to declare.
ORCID
Emily Ross  http://orcid.org/0000-0002-5165-7649 
R E FE R E N C E S
 1. Clarke AE, Shim JK, Mamo L, Fosket JR, Fishman JR. 
Biomedicalization: technoscientific transformations of health, 
Illness, and U.S. biomedicine. Am Sociol Rev. 2003;68(2):161-194.
 2. Day S, Coombes RC, McGrath-Lone L, Schoenborn C, Ward 
H. Stratified, precision or personalised medicine? cancer ser‐
vices in the ‘real world’ of a London hospital. Sociol Health Illn. 
2017;39(1):143-158.
 3. National Institute for Health and Care Excellence. Gene expression 
profiling and expanded immunohistochemistry tests for guiding ad‐
juvant chemotherapy decisions in early breast cancer management: 
MammaPrint, Oncotype DX, IHC4 and Mammostrat. Diagnostics 
guidance [DG10]. 2013.
 4. Albain KS, Barlow WE, Shak S, et al. Prognostic and predictive value 
of the 21- gene recurrence score assay in postmenopausal women 
with node- positive, oestrogen- receptor- positive breast cancer 
on chemotherapy: a retrospective analysis of a randomised trial. 
Lancet Oncol. 2010;11(1):55-65.
 5. McVeigh TP, Kerin MJ. Clinical use of the Oncotype DX genomic 
test to guide treatment decisions for patients with invasive breast 
cancer. Breast Cancer. 2017;9:393‐400.
 6. Loncaster J, Armstrong A, Howell S, et al. Impact of Oncotype DX 
breast recurrence score testing on adjuvant chemotherapy use in 
early breast cancer: real world experience in Greater Manchester, 
UK. Eur J Surg Oncol. 2017;43(5):931-937.
 7. Bell K. ‘If it almost kills you that means it’s working!’ Cultural models 
of chemotherapy expressed in a cancer support group. Soc Sci Med. 
2009;68(1):169-176.
 8. Sparano JA, Gray RJ, Makower DF, et al. Adjuvant chemotherapy 
guided by a 21- gene expression assay in breast cancer. N Engl J Med. 
2018;379(2):111-121.
 9. Spellman E, Sulayman N, Eggly S, et al. Conveying genomic recur‐
rence risk estimates to patients with early- stage breast cancer: on‐
cologist perspectives. Psychooncology. 2013;22(9):2110-2116.
 10. Gnant M, Steger GG. Fighting overtreatment in adjuvant breast 
cancer therapy. Lancet. 2009;374(9707):2029-2030.
 11. Bourret P, Keating P, Cambrosio A. Regulating diagnosis in post- 
genomic medicine: re- aligning clinical judgment? Soc Sci Med. 
2011;73(6):816-824.
 12. Rapley T. Distributed decision making: the anatomy of decisions- in- 
action. Sociol Health Illn. 2008;30(3):429-444.
 13. Charles C, Gafni A, Whelan T. Decision- making in the physician–
patient encounter: revisiting the shared treatment decision- making 
model. Soc Sci Med. 1999;49(5):651-661.
 14. Sinding C, Hudak P, Wiernikowski J, et al. “I like to be an informed 
person but…” negotiating responsibility for treatment decisions in 
cancer care. Soc Sci Med. 2010;71(6):1094-1101.
 15. Kenny P, Quine S, Shiell A, Cameron S. Participation in treatment 
decision- making by women with early stage breast cancer. Health 
Expect. 1999;2(3):159-168.
 16. Broom A. Virtually He@lthy: the impact of internet use on disease 
experience and the doctor- patient relationship. Qual Health Res. 
2005;15(3):325-345.
 17. Ziebland S, Chapple A, Dumelow C, Evans J, Prinjha S, Rozmovits L. 
How the internet affects patients’ experience of cancer: a qualita‐
tive study. BMJ. 2004;328(7439):564.
 18. Ziebland S, Wyke S. Health and Illness in a connected World: how 
might sharing experiences on the internet affect people’s health? 
Milbank Q. 2012;90(2):219-249.
 19. Hewson C, Laurent D. Research design and tools for internet re‐
search. In: Fielding N, Lee R, Blank G, eds. The Handbook of Online 
Research Methods. London, UK: SAGE; 2008:58-78.
 20. Nettleton S, Burrows R. E- Scaped medicine? information, 
Reflexivity and Health. Crit Soc Policy. 2003;23(2):165-185.
 21. Fallowfield L, Matthews L, May S, Jenkins V, Bloomfield D. 
Enhancing decision- making about adjuvant chemotherapy in early 
breast cancer following EndoPredict testing. Psychooncology. 
2018;27:1264‐1269. Online early view.
 22. Braun V, Clarke V. Using thematic analysis in psychology. Qualitat 
Res Psychol. 2006;3(2):77-101.
 23. Glaser BG. The constant comparative method of qualitative analy‐
sis. Soc Probl. 1965;12(4):436-445.
 24. British Sociological Association. Statement of Ethical Practice for 
the British Sociological Association. Secondary Statement of Ethical 
Practice for the British Sociological Association 2004. https://www.
york.ac.uk/media/abouttheuniversity/governanceandmanagement/
governance/ethicscommittee/hssec/documents/BSA%20state‐
ment%20of%20ethical%20practice.pdf. Accessed March 16, 2018.
 25. Markham A, Buchanan E. Ethical decision-making and inter‐
net research: Recommendations from the AoIR Ethics Working 
Committee (Version 2.0). 2012. http://aoir.org/ethics/. Accessed 
April 2, 2018.
 26. Samuel GN, Farsides B. The UK’s 100,000 genomes proj‐
ect: manifesting policymakers’ expectations. New Genet Soc. 
2017;36:336-353.
 27. Arribas-Ayllon M, Sarangi S, Clarke A. Genetic Testing: Accounts of 
Autonomy, Responsibility and Blame. New York, NY: Routledge; 2011.
 28. Gillespie C. The experience of risk as ‘measured vulnerability’: 
health screening and lay uses of numerical risk. Sociol Health Illn. 
2012;34(2):194-207.
82  |     ROSS et al.
 29. Sontag S. Illness as Metaphor. New York, NY: Farrar, Straus and 
Giroux; 1978.
 30. Bell K. Remaking the self: trauma, teachable moments, and 
the biopolitics of cancer survivorship. Cult Med Psychiatry. 
2012;36(4):584-600.
 31. Steinberg DL. The bad patient: estranged subjects of the cancer 
culture. Body & Society. 2015;21(3):115-143.
 32. Bell K. Biomarkers, the molecular gaze and the transformation of 
cancer survivorship. Biosocieties. 2013;8(2):124-143.
 33. Robertson A. Embodying risk, embodying political rationality: 
women’s accounts of risks for breast cancer. Health, Risk & Soc. 
2000;2(2):219-235.
 34. Charles C, Whelan T, Gafni A, Reyno L, Redko C. Doing nothing 
is no choice: lay constructions of treatment decision- making 
among women with early- stage breast cancer. Sociol Health Illn. 
1998;20(1):71-95.
 35. Bancroft EK, Castro E, Ardern-Jones A, et al. “It’s all very well reading 
the letters in the genome, but it’s a long way to being able to write”: 
men’s interpretations of undergoing genetic profiling to determine 
future risk of prostate cancer. Fam Cancer. 2014;13(4):625-635.
 36. DiMaggio P, Hargittai E, Neuman WR, Robinson JP. Social implica‐
tions of the internet. Ann Rev Sociol. 2001;27(1):307-336.
 37. Lewis J, Ritchie J. Generalising from Qualitative Research. In: Ritchie J, 
Lewis J, eds. Qualitative Research Practice: A Guide For Social Science 
Students And Researchers. London, UK: Sage; 2003:263-286.
How to cite this article: Ross E, Swallow J, Kerr A, 
Cunningham-Burley S. Online accounts of gene expression 
profiling in early- stage breast cancer: Interpreting genomic 
testing for chemotherapy decision making. Health Expect. 
2019;22:74–82. https://doi.org/10.1111/hex.12832
